scholarly journals Sample Preparation for N-Glycosylation Analysis of Therapeutic Monoclonal Antibodies by Electrophoresis

2015 ◽  
pp. 183-195 ◽  
Author(s):  
Ákos Szekrényes ◽  
Jan Partyka ◽  
Csaba Varadi ◽  
Jana Krenkova ◽  
Frantisek Foret ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Sample Preparation ◽  
Therapeutic Monoclonal Antibodies

scholarly journals A generic sample preparation approach for LC–MS/MS bioanalysis of therapeutic monoclonal antibodies in serum applied to Infliximab

2015 ◽  
Vol 1 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Anne J. Kleinnijenhuis ◽  
Jan H. Toersche ◽  
Frédérique L. van Holthoon ◽  
Richard C. Bas ◽  
William D. van Dongen
Keyword(s):  
Monoclonal Antibodies ◽  
Sample Preparation ◽  
Therapeutic Monoclonal Antibodies

Protocols for the analytical characterization of therapeutic monoclonal antibodies. II – Enzymatic and chemical sample preparation

2017 ◽  
Vol 1060 ◽  
pp. 325-335 ◽  
Author(s):  
Balazs Bobaly ◽  
Valentina D’Atri ◽  
Alexandre Goyon ◽  
Olivier Colas ◽  
Alain Beck ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Sample Preparation ◽  
Analytical Characterization ◽  
Therapeutic Monoclonal Antibodies

scholarly journals Analysis of Monoclonal Antibodies by Capillary Electrophoresis: Sample Preparation, Separation, and Detection

Separations ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 4
Author(s):  
Meriem Dadouch ◽  
Yoann Ladner ◽  
Catherine Perrin
Keyword(s):  
Capillary Electrophoresis ◽  
Monoclonal Antibodies ◽  
Sample Preparation ◽  
High Specificity ◽  
Integrated Analysis ◽  
Mass Spectrometry Detection ◽  
Analytical Characterization ◽  
Quality Issue ◽  
Therapeutic Monoclonal Antibodies ◽  
Analytical Approaches

Therapeutic monoclonal antibodies (mAbs) are dominating the biopharmaceutical field due to the fact of their high specificity in the treatment of diverse diseases. Nevertheless, mAbs are very complex glycoproteins exhibiting several macro- and microheterogeneities that may affect their safety, quality, and efficacy. This complexity is very challenging for mAbs development, formulation, and quality control. To tackle the quality issue, a combination of multiple analytical approaches is necessary. In this perspective, capillary electrophoresis has gained considerable interest over the last decade due to the fact of its complementary features to chromatographic approaches. This review provides an overview of the strategies of mAbs and derivatives analysis by capillary electrophoresis hyphenated to ultraviolet, fluorescence, and mass spectrometry detection. The main sample preparation approaches used for mAb analytical characterization (i.e., intact, middle-up/down, and bottom-up) are detailed. The different electrophoretic modes used as well as integrated analysis approaches (sample preparation and separation) are critically discussed.

An Integrated Solution-Based Rapid Sample Preparation Procedure for the Analysis of N-Glycans From Therapeutic Monoclonal Antibodies

2016 ◽  
Vol 105 (3) ◽  
pp. 1221-1232 ◽  
Author(s):  
Udayanath Aich ◽  
Aston Liu ◽  
Jude Lakbub ◽  
Jacek Mozdzanowski ◽  
Michael Byrne ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Sample Preparation ◽  
Preparation Procedure ◽  
Sample Preparation Procedure ◽  
Therapeutic Monoclonal Antibodies

Design of Innovative Therapeutic Monoclonal Antibodies

2017 ◽  
pp. 10-29
Author(s):  
A.V. Karabelskii ◽  
◽  
T.A. Nemankin ◽  
A.B. Ulitin ◽  
A.S. Vaganov ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Therapeutic Monoclonal Antibodies

Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer

2020 ◽  
Vol 20 (16) ◽  
pp. 1895-1907
Author(s):  
Navgeet Kaur ◽  
Anju Goyal ◽  
Rakesh K. Sindhu
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Clinical Practice ◽  
Therapeutic Agent ◽  
Hematologic Malignancies ◽  
Immune Checkpoints ◽  
Malignant Cells ◽  
Main Target ◽  
Therapeutic Monoclonal Antibodies ◽  
Cancerous Cells

The importance of monoclonal antibodies in oncology has increased drastically following the discovery of Milstein and Kohler. Since the first approval of the monoclonal antibody, i.e. Rituximab in 1997 by the FDA, there was a decline in further applications but this number has significantly increased over the last three decades for various therapeutic applications due to the lesser side effects in comparison to the traditional chemotherapy methods. Presently, numerous monoclonal antibodies have been approved and many are in queue for approval as a strong therapeutic agent for treating hematologic malignancies and solid tumors. The main target checkpoints for the monoclonal antibodies against cancer cells include EGFR, VEGF, CD and tyrosine kinase which are overexpressed in malignant cells. Other immune checkpoints like CTLA-4, PD-1 and PD-1 receptors targeted by the recently developed antibodies increase the capability of the immune system in destroying the cancerous cells. Here, in this review, the mechanism of action, uses and target points of the approved mAbs against cancer have been summarized.

scholarly journals COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 993
Author(s):  
Renuka Raman ◽  
Krishna J. Patel ◽  
Kishu Ranjan
Keyword(s):  
Immune Response ◽  
Monoclonal Antibodies ◽  
Severe Acute Respiratory Syndrome ◽  
Small Molecules ◽  
Viral Vector ◽  
Therapeutic Strategies ◽  
Convincing Evidence ◽  
Plasma Therapy ◽  
Therapeutic Monoclonal Antibodies ◽  
Increased Susceptibility

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities. Herein, we provide a comprehensive perspective regarding vulnerability of SARS-CoV-2 infection in patients with underlying medical comorbidities. We discuss ongoing vaccine (mRNA, protein-based, viral vector-based, etc.) and therapeutic (monoclonal antibodies, small molecules, plasma therapy, etc.) modalities designed to curb the COVID-19 pandemic. We also discuss in detail, the challenges posed by different SARS-CoV-2 variants of concern (VOC) identified across the globe and their effects on therapeutic and prophylactic interventions.

Sign in / Sign up

Export Citation Format

Share Document